Charles River Laboratories International, Inc. (CRL) earnings on May 7, 2026
More Charles River Laboratories International, Inc. earnings
Prior outlook: Optimistic Outcome: Partial
The stock initially jumped after earnings but ended the day with only a small gain. This suggests that positive early reactions were tempered by other factors.
CRL price around the earnings
185.28
Change: +2.0%
2026-05-07, 23:00 UTC
- Price: green if it ends above the starting price; red if it ends below
- End of the measured window
- Market open
- No trading (market closed)
- Starting price
Prior thesis
Prior outlook: Optimistic Outcome: Partial
- Thesis published
Guidance cut creates headwinds, but analysts remain positive.
The company recently lowered its earnings forecast, creating challenges despite strong price momentum. Analysts remain optimistic with a buy rating and a price target suggesting upside.
Context analyzed before publication
- Summary
- Mixed contexts: strong earnings history vs. recent analyst caution.
- Reasoning
- This company has a history of exceeding earnings expectations, but a recent price target reduction by a major analyst introduces uncertainty. The stock's momentum is currently flat, suggesting a neutral outlook.
- Playbook
- Given the mixed outlook, the scenario suggests waiting for clearer contexts or a more defined trend.
- Trend
- Flat momentum into earnings, indicating a neutral price trend.
Analysts
Drivers
-
Analysts
Negative
JP Morgan reduced its price target to $160, signaling a more reserved view from a key financial institution.
Evidence
- Analysts covering the stock
- 15
- Average price target
- 199.33
- Lowest price target
- 135
- Highest price target
- 265
- Upside to price target
- 8%
- Revenue growth
- -0.8%
- Forward EPS
- 12.41
- Trailing EPS
- -2.91
- Analyst moves in the last 60 days
- 2
- Strong buy: 2
- Buy: 10
- Hold: 4
- Sell: 0
- Strong sell: 1
- Strong buy
- 2
- Buy
- 10
- Hold
- 4
- Sell
- 0
- Strong sell
- 1
- April 14, 2026 · Barclays: Maintains rating (Overweight → Overweight)
- April 13, 2026 · JP Morgan: Maintains rating (Neutral → Neutral)
News and sentiment
Drivers
-
News & sentiment
Negative
The news of a reduced price target can negatively influence investor confidence before the earnings announcement.
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- Low
- Normalized volume
- 33%
News
Sources (1)
- JP Morgan Maintains Neutral on Charles River, Lowers Price Target to $160 — Benzinga
Technicals
Drivers
-
Technical
Neutral
Recent price action shows no strong directional movement, and its performance relative to the market is only slightly lagging.
Evidence
- Average true range (ATR)
- 3.7%
- Distance to 52-week high
- -19.4%
- 14-day change (14d)
- -0.0%
- 30-day change
- +11.1%
- 30-day relative strength
- -1.1%
- Benchmark change
- +12.2%
- Nearest support
- 153.7
- Nearest resistance
- 190.12
- Volume accumulation ratio
- 0.72
Trends
Evidence
- Average earnings surprise
- +10.3%
- February 18, 2026: actual EPS 2.39 vs estimate 2.35 (surprise +1.9%)
- November 5, 2025: actual EPS 2.43 vs estimate 2.34 (surprise +3.9%)
- August 6, 2025: actual EPS 3.12 vs estimate 2.55 (surprise +22.4%)
- May 7, 2025: actual EPS 2.34 vs estimate 2.07 (surprise +12.8%)
Expected move
Drivers
-
Past earnings
Positive
The company has consistently beaten earnings expectations, with an average surprise of over 10% in the past.
There is no implied-move data available for this event.
Reactions over its last 19 earnings
- Median move
- 5.7%
- 75th percentile move
- 10.2%
- 90th percentile move
- 12.8%
- Up / down moves
- 9 / 10
- Average up move
- +7.5%
- Average down move
- -6.6%
Monitoring and close
What Charles River Laboratories International, Inc. reported
There is no monitoring data available for this event.
Pre-market second reading after the results
There is no second reading available for this event.
How the stock reacted
- Outcome
- Partial
- Consolidated
- -0.0%
- Max favorable move (MFE)
- 6.7%
- Max adverse move (MAE)
- 0%